 |
50 Diseases |  |
29 Trials |
|
29 Trials |  |
3299 News |  |
| «12...2021222324252627282930...3839» |
- || Cimzia (certolizumab pegol) / Astellas, UCB
Enrollment open, Trial completion date, Trial primary completion date: CHERISH: A Study in Pregnant Women With Chronic Inflammatory Diseases Treated With Cimzia (Certolizumab Pegol) (clinicaltrials.gov) - Jun 22, 2020
P1b, N=20, Recruiting, Sponsor: UCB Biopharma S.P.R.L.
Suspended --> Recruiting | Trial completion date: Nov 2021 --> Aug 2022 | Trial primary completion date: Nov 2021 --> Aug 2022
- | Journal: Therapeutic drug monitoring with biologic agents in immune mediated inflammatory diseases. (Pubmed Central) - Jun 18, 2020
Preliminary data suggest that proactive TDM with the goal to achieve a threshold drug concentration is associated with better therapeutic outcomes when compared to empiric drug optimization and/or reactive TDM of infliximab and adalimumab in IBD. However, more data from well-designed prospective studies are needed to prove the benefit of TDM-based algorithms in real life clinical practice in IMID.
- | Clinical, Journal: Persistence and adherence of biologics in US patients with psoriatic arthritis: analyses from a claims database. (Pubmed Central) - Jun 15, 2020
However, more data from well-designed prospective studies are needed to prove the benefit of TDM-based algorithms in real life clinical practice in IMID. Patients who initiated secukinumab had the lowest discontinuation rate and highest persistence and adherence over 12 months.
- || Retrospective data, Review, Journal: Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. (Pubmed Central) - Jun 14, 2020
Living systematic reviews offer a new approach to review updating, in which the review is continually updated, incorporating relevant new evidence as it becomes available. Please refer to the Cochrane Database of Systematic Reviews for the current status of this review.
- || Cimzia (certolizumab pegol) / Astellas, UCB, Eli Lilly
Clinical, Journal: Induction of Sustained Clinical Remission in Early Axial Spondyloarthritis Following Certolizumab Pegol Treatment: 48-Week Outcomes from C-OPTIMISE. (Pubmed Central) - Jun 13, 2020
P3
Additionally, patients across the axSpA spectrum demonstrated substantial improvements in imaging outcomes and quality of life following treatment. No new safety signals were identified.
- | Enrollment open, Checkpoint inhibition: TICIMEL: TNF-Inhibitor as Immune Checkpoint Inhibitor for Advanced MELanoma (clinicaltrials.gov) - Jun 11, 2020
P1, N=30, Recruiting, Sponsor: Institut Claudius Regaud
No new safety signals were identified. Suspended --> Recruiting
- | Journal, HEOR: Cost-Effectiveness of Secukinumab Versus Other Biologics in the Treatment of Psoriatic Arthritis: An Argentinean Perspective. (Pubmed Central) - Jun 8, 2020
Suspended --> Recruiting For both biologic-naïve and experienced PsA patients, secukinumab is either a dominant or cost-effective treatment option compared with other biologics in Argentina.
- || Clinical, Review, Journal: Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review. (Pubmed Central) - Jun 8, 2020
Other biologics inhibit cytokines such as the p40 subunit of the cytokines IL-12 and IL-13 (ustekinumab), IL-17 (secukinumab, ixekizumab, bimekizumab, and brodalumab), and the p19 subunit of IL-23 (guselkumab, tildrakizumab, risankizumab, and mirikizumab)...Oral treatments include traditional agents such as methotrexate, acitretin, cyclosporine, and the advanced small molecule apremilast, which is a phosphodiesterase 4 inhibitor...Topical therapies remain the cornerstone for treating mild psoriasis. Therapeutic advancements for moderate to severe plaque psoriasis include biologics that inhibit TNF-α, p40IL-12/23, IL-17, and p19IL-23, as well as an oral phosphodiesterase 4 inhibitor.
- ||| Enbrel (etanercept) / Pfizer, Amgen, Cimzia (certolizumab pegol) / Astellas, UCB, Eli Lilly
Patterns of Rx of TNFi during pregnancy in RA. If on TNFi most used certolizumab or etanercept Abs0302 @eular_org #EULAR3020 @RheumNow @earlyarthritis @CRASCRRheum (Twitter) - Jun 4, 2020
- ||||| Orencia (abatacept) / BMS, Actemra IV (tocilizumab) / Roche, JW Pharma, Cimzia (certolizumab pegol) / Astellas, UCB, Eli Lilly
Clinical: NORD-STAR large RCT in ERA compared all with MTX: csDMARD (Triple or with steroids) or certolizumab or abatacept or tocilizumab. All Rx similar sl more CDAI remission at 24 was with ABA. ?game changer OP0018 @eular_org #EULAR2020 @RheumNow @CRASCRRheum @earlyarthritis (Twitter) - Jun 3, 2020
- ||||| Cimzia (certolizumab pegol) / Astellas, UCB, Eli Lilly
Clinical: Certolizumab Pegol: A Safe And Efficient Treatment In Patients With Uveitis During Pregnancy: Conclusion: CZP seems to be effective and safe in female patients with uveitis during pregnancy and neonates. Abstract AB1055 #EULAR2020 @RheumNow (Twitter) - Jun 3, 2020
- | Journal: Persistence rates of abatacept and TNF inhibitors used as first or second biologic DMARDs in the treatment of rheumatoid arthritis: 9 years of experience from the Rhumadata® clinical database and registry. (Pubmed Central) - May 31, 2020
Abatacept and TNFi use demonstrated similar persistence rates at 9 years as a first-line biologic agent. As a second-line biologic agent, abatacept had better persistence rates over a TNFi.
- || Cimzia (certolizumab pegol) / Astellas, UCB, Eli Lilly
Oops. My mistake. Thanks for catching that. I meant to exclude certolizumab! (Twitter) - May 30, 2020
- || Cimzia (certolizumab pegol) / Astellas, UCB, Eli Lilly
I don’t. Babies CAN get the rotavirus vaccine. The CRIB study and other studies showed no to nominal transfer of certolizumab through the placenta. (Twitter) - May 30, 2020
- || Cimzia (certolizumab pegol) / Astellas, UCB, Eli Lilly
Also, why do you recommend babies of moms on certolizumab avoid rotavirus vaccine? (Twitter) - May 30, 2020
- || For infliximab, adalimumab, certolizumab, and golimumab, I do tell moms that their babies should AVOID the rotavirus vaccination. All of those medications cross through the placenta and are contraindicated for live vaccines (Twitter) - May 30, 2020
- || Cimzia (certolizumab pegol) / Astellas, UCB, Eli Lilly
Clinical, Journal: Paradoxical Skin Reaction to Certolizumab, an Overlap of Pyoderma Gangrenosum and Psoriasis in a Young Woman Treated for Ankylosing Spondylitis: Case Report with Literature Review. (Pubmed Central) - May 26, 2020
As a second-line biologic agent, abatacept had better persistence rates over a TNFi. Paradoxical skin reactions are an emerging clinical entity that require further research in order to establish risk factors and best personalized treatment.
- Cimzia (certolizumab pegol) / Astellas, UCB, Eli Lilly
[VIRTUAL] CERTOLIZUMAB PEGOL: A SAFE AND EFFICIENT TREATMENT IN PATIENTS WITH UVEITIS DURING PREGNANCY. () - May 22, 2020 - Abstract #EULAR2020EULAR_4228;
Prednisone was reduced from a mean dose of 21.7±19.7 mg/day to 4.1±3.8 mg/day at 6 months (p=0.03), leading to complete discontinuation in 4. CZP seems to be effective and safe in female patients with uveitis during pregnancy and neonates.
- [VIRTUAL] CLINICAL CHARACTERISTICS AND TREATMENT PATTERNS OF PATIENTS WITH PSORIATIC ARTHRITIS WHO WERE PRESCRIBED BIOLOGICS: DATA FROM THE COLUMBUS REPOSITORY () - May 22, 2020 - Abstract #EULAR2020EULAR_4184;
Secukinumab initiators with PsA were more likely to be male and biologic experienced, have a higher BMI and higher RAPID3 scores indicative of more active disease vs those initiating other biologics. Additional structured and unstructured elements may need to be captured on EHR platforms to gain clarity on disease activity and treatment decisions.
- [VIRTUAL] CONVENTIONAL SYNTHETIC DMARDS IN PSORIATIC ARTHRITIS - CHANGING PRACTICE IN BIOLOGIC ERA: REAL-LIFE RESULTS FROM HURBIO-PsA REGISTRY () - May 22, 2020 - Abstract #EULAR2020EULAR_4168;
Rate of concomitant csDMARDs use remains relatively stable after starting the bDMARDs. Besides, rate of concomitant mono/csDMARD use is significantly higher after bDMARD initiation, in contrast to pre-bDMARD period.
- Cimzia (certolizumab pegol) / Astellas, UCB, Eli Lilly
[VIRTUAL] EFFECTIVENESS OF CERTOLIZUMAB IN 506 PATIENTS WITH RHEUMATOID ARTHRITIS, PSORIATIC ARTHRITIS, AND SPONDYLOARTHRITIS FROM THE APULIAN REGISTRY BIOPURE. () - May 22, 2020 - Abstract #EULAR2020EULAR_4165;
Unlike other TNF-inhibitors, the clinical response and the survival rate were also meaningful in RA patients. Table:
- Actemra IV (tocilizumab) / Roche, JW Pharma, Enbrel (etanercept) / Pfizer, Amgen, Cimzia (certolizumab pegol) / Astellas, UCB, Eli Lilly
[VIRTUAL] USE OF BIOLOGICAL DMARDS IN PATIENTS WITH ADULT-ONSET STILL’S DISEASE: RESULTS FROM TURKBIO REGISTRY (Poster View) - May 22, 2020 - Abstract #EULAR2020EULAR_4159;
According our data, TCZ and anti-IL1 agents were the most frequent biological choices. The limitation of this study was the low number of the patients with AOSD who used biological agents.
- [VIRTUAL] REASONS FOR DISCONTINUATION OF BIOLOGICS IN PATIENTS WITH REFRACTORY RHEUMATOID ARTHRITIS: RESULTS OF A RETROSPECTIVE STUDY () - May 22, 2020 - Abstract #EULAR2020EULAR_4056;
The most common reason for bDMARDs discontinuation was lack of efficacy. Additional lines of bDMARDs therapy were not associated with increasing rates of adverse events.
- [VIRTUAL] TREATMENT WITH TOFACITINIB IN REFRACTORY PSORIATIC ARTHRITIS. MULTICENTER STUDY OF 87 PATIENTS IN CLINICAL PRACTICE () - May 22, 2020 - Abstract #EULAR2020EULAR_4040;
TOFA as in RCT seems effective, rapid and relatively safe for refractory PsA. Table 1.
- Enbrel (etanercept) / Pfizer, Amgen, Humira (adalimumab) / Eisai, AbbVie, Cimzia (certolizumab pegol) / Astellas, UCB, Eli Lilly
[VIRTUAL] PREGNANCY AND INFLAMMATORY ARTHROPATIES: EXPERIENCE IN A MULTIDISCIPLINARY UNIT () - May 22, 2020 - Abstract #EULAR2020EULAR_4001;
Given the low number of patients receiving biological treatment no conclusions about complications and evolution of the disease can be drawn, so further investigation are needed in this group of patients. Monitoring inflammatory arthropathies in a multidisciplinary unit increases the chances of successful pregnancies.
- [VIRTUAL] THE INFLUENCE OF OBESITY ON BIOLOGICAL DMARD TREATMENT RESPONSE IN PSORIATIC ARTHRITIS: HUR-BIO REAL LIFE RESULTS () - May 22, 2020 - Abstract #EULAR2020EULAR_3948;
Obesity was associated with higher disease activity and poorer effect of bDMARD treatment in patients with PsA. In obese PsA patients with high disease activity despite bDMARD therapy, intentional weight loss may be recommended as an adjunctive therapy.
- [VIRTUAL] IMMUNOSUPPRESSIVE AND IMMONOMODULATING AGENTS IN RHEUMATOID ARTHRITIS: A SYSTEMATIC REVIEW OF CLINICAL TRIALS AND THEIR CURRENT DEVELOPMENT STAGE () - May 22, 2020 - Abstract #EULAR2020EULAR_3832;
This development does not always lead to new treatments since 141 (58%) have already been withdrawn. Hopefully, some of the currently evaluated drugs will contribute to improve the therapeutic management of RA patients, requiring a greater personalization of therapeutic strategies, both in the choice of molecules and their place in therapeutic sequences.
- [VIRTUAL] CHOROIDAL THICKNESS IS A BIOMARKER AND CAN PREDICT THE RESPONSE TO TREATMENT IN ANKYLOSING SPONDYLITIS () - May 22, 2020 - Abstract #EULAR2020EULAR_3823;
CT and CPR had a 95% concordance. A high CT is associated with risk of failure to biological treatment.
- [VIRTUAL] PATIENT CHARACTERISTICS, TREATMENT PATTERNS, AND RESOURCE UTILIZATION OF SJOGREN’S SYNDROME PATIENTS IN A LARGE US HEALTH NETWORK (Poster View) - May 22, 2020 - Abstract #EULAR2020EULAR_3778;
Baseline Demographic and Clinical Pts Characteristics 1 cevimeline, pilocarpine hydrochloride, ophthalmic insert etc; 2 aspirin, ibuprofen, naproxen; 3 methotrexate, hydroxychloroquine, sulfasalazine, leflunomide, myophenolate mofetil, azathioprine; 4 prednisone; 5 sarilumab, belimumab, ustekinumab, infliximab, adalimumab, certolizumab pegol, golimumab, etanercept, abatacept, tocilizumab, rituximab, tofacitinib, baricitinib Figure 1. Observation of higher comorbidities suggests substantial burden of SS pts on healthcare system, with majority of pts being diagnosed outside of rheumatology offices.
- [VIRTUAL] PREVALENCE OF EXTRA-ARTICULAR MANIFESTATIONS AND IMPACT ON TARGETED DRUG PRESCRIPTION IN PATIENTS WITH SPONDYLOARTHRITIS: A RETROSPECTIVE ANALYSIS OF A REAL-LIFE COHORT () - May 22, 2020 - Abstract #EULAR2020EULAR_3727;
In our real-life cohort of SpA patients treated with targeted therapies, EAMs were highly represented at baseline, especially uveitis in axSpA and IBD in peripheral SpA. The presence of extra-articular involvement was associated with a preferential prescription of anti-TNF monoclonal antibodies rather than etanercept or drugs with different mechanisms of action.
- [VIRTUAL] BIOLOGICAL THERAPIES IN JUVENILE IDIOPHATIC ARTHRITIS: ARE THERE ANY DIFFERENCES BETWEEN CATEGORIES? () - May 22, 2020 - Abstract #EULAR2020EULAR_3701;
OligE and PolyRF - showed a high rate of change of the first BT related to secondary failure of Etanercept and Infliximab when compared to Adalimumab and Tocilizumab, as described in the survival analysis. The category with the highest retention of the first BT was ERA.
- Cimzia (certolizumab pegol) / Astellas, UCB, Eli Lilly
[VIRTUAL] DAS28-REMISSION IS ASSOCIATED WITH AN INCREASE OF FINGER JOINT SPACE WIDTH IN PATIENTS WITH RHEUMATOID ARTHRITIS (Poster View) - May 22, 2020 - Abstract #EULAR2020EULAR_3593;
These patients were treated with certolizumab pegol 200 mg (every two weeks) plus methotrexate and certolizumab pegol 400 mg (every two weeks) plus methotrexate. The study highlights that patients treated with certolizumab pegol plus methotrexat and a DAS-Remission showed an increase of joint space width of the metacarpal-phalangeal articulations which is potentially associated with reparative effects of the cartilage under the anti-TNF treatment with certolizumab pegol.
- [VIRTUAL] ASSOCIATIONS BETWEEN JOINT REPLACEMENT HISTORY AND CYCLIC CITRULLINATED PEPTIDE ANTIBODY TITERS IN RHEUMATOID ARTHRITIS PATIENTS () - May 22, 2020 - Abstract #EULAR2020EULAR_3375;
With one exception, all RA patients who underwent joint replacement were positive for anti-CCP, and their titers were higher than non-surgical cases. Practitioners should be aware of this trend, and pay attention to the progression of damage in the knee and hip joints when treating RA patients with high anti-CCP titers.
- Cimzia (certolizumab pegol) / Astellas, UCB, Eli Lilly
[VIRTUAL] EFFECT ON RETENTION RATES OF A NOVEL AUTOINJECTOR E-DEVICE IMPLEMENTED IN CLINICAL PRACTICE IN PATIENTS WITH CHRONIC ARTHRITIS TREATED WITH CERTOLIZUMAB PEGOL; A MULTI-CENTRE STUDY () - May 22, 2020 - Abstract #EULAR2020EULAR_3282;
The reasons for withdrawal was primarily patient request. Thus, the injection experience must be tailored carefully when selecting patients for new autoinjector e-Devices to enhance retention on device and patient satisfaction.
- Enbrel (etanercept) / Pfizer, Amgen, Cimzia (certolizumab pegol) / Astellas, UCB, Eli Lilly
[VIRTUAL] PREGNANCY IN WOMEN WITH SPONDYLOARTHRITIS: WHO ARE THE PATIENTS AT RISK OF DISEASE FLARE? (Poster View) - May 22, 2020 - Abstract #EULAR2020EULAR_3220;
Flares occurred especially in those patients who discontinued TNFi early in pregnancy and with axial involvement. When resumed during pregnancy, TNFi was able to control the disease.
- [VIRTUAL] CO-MEDICATIONS MAY ALTER THE RESPONSE TO TNF-INHIBITORS IN SPONDYLOARTHRITIS PATIENTS: A PHARMACOMICROBIOMIC EFFECT? () - May 22, 2020 - Abstract #EULAR2020EULAR_3131;
The hypothesis that this effect is due to their interference with the gut microbiota is only speculative but, regardless the reason of this interaction, clinician should be aware of the potential negative effect of these co-medication on TNF-i. Figure 1.
- [VIRTUAL] USE OF TNF-INHIBITORS BEFORE, DURING AND THE FIRST YEAR AFTER PREGNANCY AMONG WOMEN WITH RHEUMATOID ARTHRITIS () - May 22, 2020 - Abstract #EULAR2020EULAR_3094;
Most of the women with rheumatic arthritis were not treated with TNF inhibitors before or in pregnancy. Women with rheumatic arthritis that continuing treatment with TNF inhibitors through pregnancy were using certilozumab and etanercept.
- Cimzia (certolizumab pegol) / Astellas, UCB, Eli Lilly
[VIRTUAL] PRESCRIPTION PATTERNS AND DISEASE ACTIVITY IN PORTUGUESE WOMEN OF CHILDBEARING AGE WITH RHEUMATOID ARTHRITIS, PSORIATIC ARTHRITIS, ANKYLOSING SPONDYLITIS AND JUVENILE IDIOPATHIC ARTHRITIS () - May 22, 2020 - Abstract #EULAR2020EULAR_3043;
Nevertheless, DA in this group was not well controlled, which may influence future pregnancy outcomes. Ensuring tight DA control in WoCBA through proper and ideally no teratogenic medication remains an unmet clinical need.
- [VIRTUAL] BEHCET’S DISEASE: CLINICAL FEATURES AND OFF-LABEL BIOLOGIC TREATMENT STRATEGIES () - May 22, 2020 - Abstract #EULAR2020EULAR_3020;
The most frequent indications were musculoskeletal, neurological or intestinal involvement. Biologic agents were a generally effective and safe therapeutic approach.
- Cimzia (certolizumab pegol) / Astellas, UCB, Eli Lilly
[VIRTUAL] GESTATIONAL DESIRE AND CERTOLIZUMAB PEGOL IN PATIENTS WITH CHRONIC INFLAMMATORY RHEUMATIC DISEASE. PRELIMINARY RESULTS OF THE GESTAMAD COHORT (Poster View) - May 22, 2020 - Abstract #EULAR2020EULAR_3015;
Women diagnosed with PsA and axSpA have a high rate of previous abortions, upper than 25%. The duration of the disease is equally long at the time of manifesting gestational desire.
- [VIRTUAL] INFLAMMATORY BOWEL DISEASE IN PSORIATIC ARTHRITIS. STUDY OF 306 PATIENTS FROM A SINGLE UNIVERSITARY CENTER. PREVALENCE, CLINICAL FEATURES AND RELATIONSHIP TO BIOLOGIC THERAPY. () - May 22, 2020 - Abstract #EULAR2020EULAR_3012;
The duration of the disease is equally long at the time of manifesting gestational desire. IBD in PsA was uncommon (3.3%), may be associated to a more severe PsA, and no relationship to BT was found.
- [VIRTUAL] POOLED ANALYSIS OF ASSOCIATION BETWEEN ABATACEPT OR OTHER TARGET DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (TDMARD) AND TYPE 2 DIABETES MELLITUS (T2DM)-RELATED HEALTHCARE RESOURCE UTILIZATION (HCRU) AND COSTS IN TNFI-NAÏVE RHEUMATOID ARTHRITIS (RA) PATIENTS WITH T2DM () - May 22, 2020 - Abstract #EULAR2020EULAR_2957;
TNFi-naive RA patients with T2DM newly initiating abatacept had lower adjusted rates of T2DM-related hospitalizations compared to patients who initiated a non-TNFi or a TNFi. Total costs were lower among patients initiating abatacept vs. patients who initiated a non-TNFi or a TNFi.
- [VIRTUAL] BAFF CONTRIBUTES TO THE DEVELOPMENT OF IMMUNOGENICITY IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH TNF INHIBITORS (Poster View) - May 22, 2020 - Abstract #EULAR2020EULAR_2911;
Nevertheless, this association depends on the age. In RA patients treated with TNFi, the development of ADA within 6m is associated with higher baseline BAFF concentration only in older patients but not in younger patients.
- [VIRTUAL] COMPARATIVE EFFICACY (DAS 28) OF TOCILIZUMAB AND OTHER TARGETED IMMUNE MODULATORS (TIMS) FOR RHEUMATOID ARTHRITIS: A NETWORK META-ANALYSIS (NMA) () - May 22, 2020 - Abstract #EULAR2020EULAR_2804;
Objectives: To evaluate the relative efficacy of intravenous (IV) and subcutaneous (SC) tocilizumab plus a conventional disease modifying antirheumatic drug (cDMARD) to other TIMs plus a cDMARD in TIM-naïve or mixed (<20% TIM-experienced) adults with moderate to severe RA...Treatments included Janus kinase (JAK) inhibitors (upadacitinib, baricitinib, and tofacitinib), tumor necrosis factor alpha inhibitors (TNFi; adalimumab, certolizumab pegol, golimumab, and infliximab), and other non-TNFis (rituximab, sarilumab, tocilizumab, and abatacept)... Results of this NMA demonstrate that tocilizumab is associated with a greater likelihood of remission (DAS28 <2.6) at 12 and 24 weeks compared to most other TIMs including new JAK inhibitors, when used in combination with a cDMARD among TIM-naïve/mixed patient populations.
- [VIRTUAL] RISK FACTORS FOR THE POSTOPERATIVE DELAYED WOUND HEALING IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH A BIOLOGICAL AGENT (Poster View) - May 22, 2020 - Abstract #EULAR2020EULAR_2799;
As previous study on tocilizumab described, the current retrospective study suggested that pre-operative use of tocilizumab and procedures in the foot and ankle were risk factors for DWH. Pre-operative disease activity and nutritional status were not independent risk factors for an increase in the prevalence of DWH.
- [VIRTUAL] CERTOLIZUMAB PEGOL IN PATIENTS WITH RHEUMATOID ARTHRITIS: POOLED EFFICACY ANALYSIS OF PHASE 3 CLINICAL TRIALS ACROSS BASELINE RHEUMATOID FACTOR QUARTILES (Poster View) - May 22, 2020 - Abstract #EULAR2020EULAR_2795;
P2/3, P3
In this pooled post-hoc analysis, efficacy of CZP appeared to be consistent and independent of RF levels; observed efficacy may be related to the unique molecular structure of CZP. CZP treatment in association with MTX may be a feasible option in pts with RA regardless of baseline RF status.
- Enbrel (etanercept) / Pfizer, Amgen, Cimzia (certolizumab pegol) / Astellas, UCB, Eli Lilly
[VIRTUAL] SOLUBLE VASCULAR BIOMARKERS IN RHEUMATOID ARTHRITIS AND ANKYLOSING SPONDYLITIS: EFFECTS OF ONE-YEAR ANTI-TNF-Α THERAPY (Poster View) - May 22, 2020 - Abstract #EULAR2020EULAR_2726;
This therapy also decreased suPAR levels in patients with critically high suPAR. BNP fragment levels were associated with seropositivity in RA.
- [VIRTUAL] ANTI-IL-6 RECEPTOR ANTIBODY AMELIORATES DISEASE ACTIVITY OF RHEUMATOID ARTHRITIS PATIENTS WITH KNEE JOINT INVOLVEMENT -ANSWER COHORT STUDY- (Poster View) - May 22, 2020 - Abstract #EULAR2020EULAR_2719;
TNFi group includes 25 adalimumab, 25 certolizumab pegol, 14 etanercept, 54 golimumab and 30 infliximab treated patients... Thus, these findings suggest that anti-IL-6 receptor antibody was more effective in the RA patients with knee joint involvement compared to TNF- inhibitor.
- [VIRTUAL] PERSISTENCE IN USE OF BIOLOGIC DISEASE MODIFYING ANTIRHEUMATIC DRUGS TREATMENT IN PATIENTS WITH PSORIATIC ARTHRITIS () - May 22, 2020 - Abstract #EULAR2020EULAR_2701;
However, the sensitivity analysis indicates that some patients may resume their initial treatment beyond the indicated refill intervals. Further investigations are needed to clarify whether this is due to a better treatment effectiveness or adverse effects associated with IL inhibitors.
- [VIRTUAL] EVALUATION OF ENTHESITIS INDICES AND RESPONSE TO BDMARD THERAPY IN PORTUGUESE PATIENTS WITH SPONDYLOARTHRITIS (Poster Tour) - May 22, 2020 - Abstract #EULAR2020EULAR_2682;
The initiation of bDMARD led to improved enthesitis indices over a 24-month period. ΔLEI correlates better with SpA activity scores and measurements than the other indices, especially at the first 12 months of initiation of bDMARD therapy.